A Nontoxic Adjuvant Treatment for Advanced Head and Neck Cancer
- 1 December 1983
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 109 (12), 789-791
- https://doi.org/10.1001/archotol.1983.00800260011003
Abstract
• A variety of adjuvant chemotherapy programs have been described for advanced head and neck cancer. The protocol described herein is nontoxic and particularly appropriate for patients with advanced tumors who cannot, because of severe pulmonary disease, tolerate bleomycin sulfate. Eighty percent of patients treated with this combination responded with more than 50% tumor shrinkage. Chemotherapy was followed by either surgery, radiation therapy, or both. Long-term control with this combined modality therapy was better in oral cavity and oropharyngeal lesions than in tumors from the hypopharynx. (Arch Otolaryngol 1983;109:789-791)This publication has 5 references indexed in Scilit:
- Chemotherapy in Head and Neck CancerNew England Journal of Medicine, 1983
- Preoperative chemotherapy for osteogenic sarcoma:Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapyCancer, 1982
- CLINICAL-TRIAL OF CISPLATIN AND 5-FU INFUSION AS INITIAL TREATMENT FOR ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK1982
- Phase I study of protracted venous infusion of 5-fluorouracilCancer, 1981
- Combination chemotherapy with vinblastine, bleomycin, and cis‐diamminedichloroplatinum (ii) in squamous cell carcinoma of the head and neckCancer, 1980